Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott J Rodig

Showing results (161-170 of 293) with videos related to

Pageof 30
Sort By:
Science Translational Medicine|July 20, 2018
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanomaScott J Rodig, Daniel Gusenleitner, Donald G Jackson, et al.
The Journal of Molecular Diagnostics : JMD|December 4, 2014
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimensChristopher D Carey, Daniel Gusenleitner, Bjoern Chapuy, et al.
Cancer|April 8, 2014
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer NetworkAlex F Herrera, Allison Crosby-Thompson, Jonathan W Friedberg, et al.
Blood|October 16, 2016
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphomaCaron Jacobson, Nadja Kopp, Jacob V Layer, et al.
Development (Cambridge, England)|June 10, 2010
CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cellsKaren B O'Brien, Meritxell Alberich-Jordà, Neelu Yadav, et al.
Nature Medicine|June 28, 2011
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNeil Johnson, Yu-Chen Li, Zandra E Walton, et al.
Journal for Immunotherapy of Cancer|November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJoao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Cancer Cell|September 15, 2012
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphomaStefano Monti, Bjoern Chapuy, Kunihiko Takeyama, et al.
Oncoimmunology|December 19, 2024
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumabJiajia Chen, Giuseppe Tarantino, Mariano Severgnini, et al.
British Journal of Cancer|September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignanciesMonica M Mita, Alain C Mita, Jennifer L Moseley, et al.
Pageof 30

Showing results (161-170 of 293) with videos related to

Sort By:
Pageof 30
Science Translational Medicine|July 20, 2018
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanomaScott J Rodig, Daniel Gusenleitner, Donald G Jackson, et al.
The Journal of Molecular Diagnostics : JMD|December 4, 2014
Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimensChristopher D Carey, Daniel Gusenleitner, Bjoern Chapuy, et al.
Cancer|April 8, 2014
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer NetworkAlex F Herrera, Allison Crosby-Thompson, Jonathan W Friedberg, et al.
Blood|October 16, 2016
HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphomaCaron Jacobson, Nadja Kopp, Jacob V Layer, et al.
Development (Cambridge, England)|June 10, 2010
CARM1 is required for proper control of proliferation and differentiation of pulmonary epithelial cellsKaren B O'Brien, Meritxell Alberich-Jordà, Neelu Yadav, et al.
Nature Medicine|June 28, 2011
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibitionNeil Johnson, Yu-Chen Li, Zandra E Walton, et al.
Journal for Immunotherapy of Cancer|November 26, 2021
Low peripheral blood derived neutrophil-to-lymphocyte ratio (dNLR) is associated with increased tumor T-cell infiltration and favorable outcomes to first-line pembrolizumab in non-small cell lung cancerJoao V Alessi, Biagio Ricciuti, Stephanie L Alden, et al.
Cancer Cell|September 15, 2012
Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphomaStefano Monti, Bjoern Chapuy, Kunihiko Takeyama, et al.
Oncoimmunology|December 19, 2024
Circulating cytokine associations with clinical outcomes in melanoma patients treated with combination nivolumab plus ipilimumabJiajia Chen, Giuseppe Tarantino, Mariano Severgnini, et al.
British Journal of Cancer|September 1, 2017
Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignanciesMonica M Mita, Alain C Mita, Jennifer L Moseley, et al.
Pageof 30